How should atomoxetine (Strattera) and bupropion (Wellbutrin) be started and titrated in an adult without seizure history, uncontrolled hypertension, MAO inhibitor use, or severe hepatic impairment for ADHD with co‑existing depression?

Combination Therapy with Atomoxetine and Bupropion for ADHD with Comorbid Depression

For an adult with ADHD and comorbid depression without contraindications, start atomoxetine at 40 mg daily for ADHD and bupropion at 150 mg daily for depression, titrating each independently based on response.

Rationale for Combination Therapy

The evidence strongly supports treating both conditions simultaneously rather than sequentially. While older guidelines 1 suggested treating ADHD first with stimulants and reassessing depression afterward, this approach is less applicable when using non-stimulants for patients who may prefer to avoid stimulants or have concerns about their use.

Atomoxetine is specifically effective for ADHD with comorbid conditions 2, showing efficacy without exacerbating depression or anxiety. The drug has demonstrated benefit across 50 clinical studies in patients with ADHD and psychiatric comorbidities, maintaining effectiveness regardless of the comorbid disorder 2.

Bupropion addresses depression while providing modest ADHD benefit 1. Though classified as a "second-line agent at best" for ADHD 1, it offers proven antidepressant activity in adults and can provide supplementary ADHD symptom control 3, 4. Recent evidence shows bupropion significantly reduces ADHD symptoms compared to placebo (standardized mean difference -0.50) 4, though it remains less efficacious than stimulants 5.

Atomoxetine Initiation and Titration

Starting dose: 40 mg once daily 6

Titration schedule:

• Maintain 40 mg for minimum 3 days
• Increase to target dose of 80 mg after 3 days, given either once daily (morning) or split into morning and late afternoon/evening doses 6
• After 2-4 additional weeks at 80 mg, may increase to maximum 100 mg if optimal response not achieved 6
• Maximum dose: 100 mg daily 6

Key monitoring points:

• Atomoxetine carries a black box warning for suicidal ideation in children/adolescents 7, though adult trials did not show this risk 7. Monitor mood closely during initial weeks and dose changes
• Check blood pressure regularly—atomoxetine can cause hypertension 8 and rare hypertensive crisis 8
• Monitor for hepatotoxicity: atomoxetine shows higher reporting frequency of drug-induced liver injury compared to methylphenidate (ROR 6.42) 9. Avoid in patients with hepatic impairment 6
• Common side effects: nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence 7

Important drug interaction: If patient takes strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine), start atomoxetine at 40 mg and only increase to 80 mg after 4 weeks if symptoms persist and initial dose is tolerated 6

Bupropion Initiation and Titration

Starting dose: 150 mg once daily in the morning (extended-release formulation) 10

Titration schedule:

• Maintain 150 mg for at least 3 days
• Increase by 37.5-75 mg increments every 3 days as tolerated 10
• Target dose: 150 mg twice daily 10
• Maximum dose: 300 mg daily (given as 150 mg twice daily) 10
• Give second dose before 3 PM to minimize insomnia 10

Critical safety considerations:

• Absolute contraindication with MAO inhibitors: Do not use within 14 days of MAOI 1
• Seizure risk: Bupropion lowers seizure threshold. Though patient has no seizure history, this remains the most significant risk. Avoid doses above 300 mg daily 10
• Activating properties: Expect rapid improvement in energy level 10. Do not use if patient has significant agitation 10
• Cardiovascular effects: Monitor for tachycardia and QT prolongation, particularly at higher doses 11

Common side effects in adults: Dry mouth, insomnia, nausea, decreased appetite, constipation, dizziness 10. Sexual dysfunction occurs in ~2% 10, which may be beneficial if patient experiences sexual side effects from other antidepressants.

Clinical Monitoring Algorithm

Week 1-3:

• Weekly contact (phone acceptable) to assess tolerability and side effects
• Monitor blood pressure at each contact for atomoxetine
• Assess for activation, insomnia, or mood changes

Week 4:

• In-person visit to assess ADHD symptom response and depressive symptoms
• Obtain rating scales (ADHD symptoms, depression severity)
• Adjust doses based on response:
  • If ADHD symptoms persist: increase atomoxetine toward 100 mg
  • If depression persists: increase bupropion toward 300 mg daily
  • If both respond adequately: maintain current doses

Week 8-12:

• Reassess both conditions
• By this point, atomoxetine should show full effect (takes 2-4 weeks longer than stimulants)
• Bupropion antidepressant effects require 4-8 weeks for full assessment 10

Ongoing maintenance:

• Monthly visits until symptoms stabilized
• Monitor weight, blood pressure, heart rate at each visit
• Periodic reassessment of continued need for both medications

Common Pitfalls to Avoid

1. Don't wait to treat depression: The older approach of treating ADHD first and reassessing depression later 1 delays necessary treatment and increases patient suffering

2. Don't underdose atomoxetine: Many patients require the full 80-100 mg dose. The 40 mg starting dose is often insufficient 6

3. Don't exceed bupropion 300 mg daily: Higher doses substantially increase seizure risk without proven additional benefit 10

4. Don't ignore the 3-day minimum: Both medications require this interval before dose increases to assess tolerability 6, 10

5. Don't combine with MAOIs: Absolute contraindication for bupropion 1

6. Don't overlook CYP2D6 interactions: SSRIs like fluoxetine and paroxetine significantly increase atomoxetine levels, requiring dose adjustment 6

This combination provides comprehensive treatment for both conditions with complementary mechanisms—atomoxetine's noradrenergic effects for ADHD and bupropion's dopaminergic/noradrenergic effects for depression—while avoiding stimulant-related concerns and the sexual dysfunction common with SSRIs.